Aktuellt
SENASTE
Prostatype Genomics has proposed a SEK 34.3m funding (new issue of shares with preferential rights for existing shareholders) which is guaranteed and underwritten by 70%. A new study supporting the Prostatype test was based on 71 patients. The study outcome suggested a strong correlation between the prognostic score and the status confirmed by the tissue secured from the subsequent surgery. This is good news, but the funding will also result in a substantial dilution, and our base case outlook will be updated and changed.
LÄS MER
